About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
AMGN - Amgen Inc.| Previous Close | $224.84 | Open | $225.50 |
| Volume | 1.27M | Market Cap | 132.473B |
| Yield | 2.54 % | Last Dividend | $5.67 |
| Amgen : The underlying trend is in force... | 01/28/20 |
| Amgen shares show a positive technical situation which suggests a continuation of the upward dynamic over the medium term. | January 28, 2020 | |
| Amgen Announces Webcast Of 2019 Fourth Q... | 01/27/20 |
| THOUSAND OAKS, Calif., Jan. 27, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2019 fin... | |
| Bristol-Myers Squibb is planning to laun... | 01/27/20 |
| The newly combined Bristol-Myers Squibb and Celgene is shaping up to be a formidable company in the pharmaceutical industry. It's now looking at eight... | |
| The Week Ahead In Biotech: Amgen, Eli Li... | 01/26/20 |
| Biotech stocks haven't seen much of a momentum thus far in the new year amid a lack of meaningful catalysts. The bygone week saw two FDA approvals: Ho... | |
| Global Stroke Treatment Market Report 20... | 01/24/20 |
| DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The "Stroke Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027"... | |
| Amgen Stock Falls 3% | 01/24/20 |
| https://www.investing.com/news/stock-market-news/amgen-stock-falls-3-2067228 | |
| Amgen Stock Is Poised to Gain in 2020, A... | 01/23/20 |
| Citi???s Mohit Bansal rates the stock a Buy and increased his price target to $275 from $245. | |
| Granulocyte Macrophage Colony Stimulatin... | 01/20/20 |
| DUBLIN--(BUSINESS WIRE)--The "Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAn... | |
| Serine Threonine Protein Kinase Pim 2, P... | 01/17/20 |
| DUBLIN--(BUSINESS WIRE)--The "Serine Threonine Protein Kinase Pim 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.co... | |
| Should Value Investors Consider Amgen (A... | 01/16/20 |
| Let's see if Amgen (AMGN) stock is a good choice for value-oriented investors right now from multiple angles. | |
| Buy rating | 01/23/20 |
| Citigroup maintains Buy rating and raises Price Target from $245.00 to $275.00 | |
| Hold rating | 01/22/20 |
| UBS maintains Neutral rating and raises Price Target from $194.00 to $238.00 | |
| Strong Buy rating | 01/17/20 |
| Morgan Stanley maintains Overweight rating and lowers Price Target from $280.00 to $277.00 | |
| Strong Buy rating | 01/09/20 |
| BMO Capital maintains Outperform rating and raises Price Target from $240.00 to $275.00 | |
| Strong Buy rating | 12/20/19 |
| Cowen & Co. maintains Outperform rating and raises Price Target from $253.00 to $277.00 | |
| Strong Buy rating | 12/17/19 |
| and announces Price Target of $280.00 | |
| Buy rating | 12/16/19 |
| Goldman Sachs maintains Buy rating and raises Price Target from $263.00 to $270.00 | |
| Buy rating | 12/09/19 |
| Argus Research maintains Buy rating and raises Price Target from $240.00 to $265.00 | |
| Buy rating | 11/12/19 |
| SunTrust Robinson Humphrey initiates coverage with Buy rating and announces Price Target of $256.00 | |
| Strong Buy rating | 11/05/19 |
| Cantor Fitzgerald upgrades from Neutral to Overweight rating and raises Price Target from $230.00 to $255.00 | |
| Hold rating | 10/17/19 |
| and announces Price Target of $215.00 | |
| Hold rating | 09/05/19 |
| and raises Price Target from $221.00 to $230.00 | |
| Hold rating | 08/29/19 |
| JP Morgan maintains Neutral rating and raises Price Target from $191.00 to $198.00 | |
| Hold rating | 08/27/19 |
| RBC Capital maintains Sector Perform rating and raises Price Target from $192.00 to $206.00 | |
| Strong Buy rating | 08/27/19 |
| BMO Capital maintains Outperform rating and raises Price Target from $230.00 to $240.00 | |
| Hold rating | 08/19/19 |
| Mizuho downgrades from Buy to Neutral rating and raises Price Target from $208.00 to $212.00 | |
| Strong Buy rating | 08/16/19 |
| and raises Price Target from $202.00 to $225.00 | |
| Strong Buy rating | 08/13/19 |
| Oppenheimer maintains Outperform rating and raises Price Target from $210.00 to $230.00 | |
| Buy rating | 08/12/19 |
| Wells Fargo maintains Market Perform rating and raises Price Target from $197.00 to $202.00 | |
| Date | 2020-01-30 (AMC) | Est. (EPS/Rev.) | $3.52/ 6.09B |
| Actual (EPS/Rev.) | / | EPS (TTM) | 13.11 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Alpha Swing Trades | Jonathan | 69.00 % | Follow |
| Hi America | Lawrence | 62.00 % | Subscribe |
| LetsGrow - Growth Stocks | BigMoveTrader | 58.00 % | Follow |
| Fibonacci Trading | Arez | 56.00 % | Subscribe |
| Burdeshaw Investing | Matthew Burdeshaw | 55.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
